RIGL

+ Watchlist + Portfolio

Rigel Pharmaceuticals, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $46.97
52-Week Range: $24.95 – $52.24
Market Cap: $872.37M
P/E (TTM): 2.79
EPS (TTM): 16.88
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.07
PEG Ratio: —
Return on Equity: 126.90%
Return on Assets: 14.95%
Gross Margin: 75.61%
Operating Margin: 29.95%
Profit Margin: 116.30%
Current Ratio: 1.94
Debt/Equity: 0.09
Total Debt: $39.95M
Free Cash Flow: $-31.76M
Revenue Growth: -22.60%
Earnings Growth: -73.20%
Enterprise Value: $825.38M

RIGL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$120.24M	$116.88M	$179.28M	$294.28M
Cost of Revenue	$1.75M	$7.11M	$18.65M	$19.62M
Gross Profit	$118.49M	$109.77M	$160.63M	$274.66M
Research & Development	$60.27M	$24.52M	$23.38M	$33.30M
Selling, General & Admin	$112.45M	$105.74M	$113.06M	$115.90M
Operating Expenses	$172.72M	$130.26M	$136.44M	$149.19M
Operating Income	-$54.23M	-$20.49M	$24.19M	$125.47M
EBITDA	-$53.87M	-$16.98M	$28.51M	$131.56M
Pretax Income	-$58.57M	-$25.09M	$18.37M	$121.83M
Income Tax	$0.00	$0.00	$881.00K	-$245.20M
Net Income	-$58.57M	-$25.09M	$17.48M	$367.02M
Diluted EPS	-3.40	-1.44	0.99	19.48
Diluted Shares	17.24M	17.40M	17.69M	18.84M

RIGL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$24.46M	$32.79M	$56.75M	$40.58M
Receivables	$40.32M	$30.55M	$41.62M	$51.76M
Inventory	$9.12M	$5.52M	$6.00M	$11.51M
Current Assets	$115.90M	$99.27M	$135.10M	$240.17M
Total Assets	$134.28M	$117.22M	$163.98M	$513.59M
Current Liabilities	$65.21M	$53.27M	$63.30M	$99.24M
Long-Term Debt	$39.45M	$52.37M	$52.41M	$22.48M
Total Debt	$41.55M	$60.58M	$59.97M	$53.30M
Total Liabilities	$147.90M	$145.87M	$160.69M	$122.11M
Retained Earnings	-$1.38B	-$1.41B	-$1.39B	-$1.02B
Shareholders' Equity	-$13.62M	-$28.64M	$3.29M	$391.48M
Working Capital	$50.69M	$46.00M	$71.80M	$140.93M
Net Debt	$14.99M	$26.82M	$2.93M	$11.71M

RIGL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$73.76M	-$5.74M	$31.47M	$75.66M
Capital Expenditure	-$450.00K	-$15.00M	-$396.00K	—
Free Cash Flow	-$74.21M	-$20.74M	$31.07M	$75.66M
Depreciation & Amortisation	$998.00K	$1.24M	$2.23M	$2.42M
Stock-Based Compensation	$12.38M	$8.81M	$12.39M	$12.71M
Investing Cash Flow	$72.78M	-$4.30M	$4.13M	-$92.36M
Financing Cash Flow	$6.55M	$18.37M	-$11.64M	$601.00K
Share Repurchases	$0.00	$0.00	-$10.00M	$0.00
Net Change in Cash	$5.57M	$8.33M	$23.96M	-$16.11M

RIGL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$53.33M	$101.69M	$69.46M	$69.80M	$58.82M	$78.70M
Cost of Revenue	$4.41M	$4.50M	$4.75M	$5.96M	$4.61M	$8.53M
Gross Profit	$48.92M	$97.18M	$64.71M	$63.85M	$54.21M	$70.18M
Research & Development	$8.44M	$6.82M	$7.35M	$10.69M	$11.68M	$13.96M
Selling, General & Admin	$27.71M	$29.26M	$28.94M	$29.99M	$30.65M	$32.64M
Operating Expenses	$36.15M	$36.08M	$36.29M	$40.68M	$42.33M	$46.60M
Operating Income	$12.77M	$61.10M	$28.42M	$23.17M	$11.88M	$23.57M
EBITDA	$13.97M	$62.46M	$30.12M	$25.01M	$13.69M	$25.21M
Pretax Income	$11.51M	$59.98M	$27.62M	$22.71M	$11.66M	$23.59M
Income Tax	$65.00K	$369.00K	-$280.00K	-$245.35M	$3.00M	$6.29M
Net Income	$11.45M	$59.61M	$27.90M	$268.06M	$8.65M	$17.29M
Diluted EPS	0.63	3.28	1.46	13.54	0.44	0.88
Diluted Shares	18.17M	18.16M	19.16M	19.79M	19.69M	19.57M

RIGL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$45.73M	$53.41M	$48.53M	$40.58M	$24.41M	$60.82M
Receivables	$41.55M	$39.91M	$45.92M	$51.76M	$49.95M	$56.04M
Inventory	$4.66M	$10.42M	$13.30M	$11.51M	$11.65M	$14.37M
Current Assets	$146.56M	$175.39M	$214.93M	$240.17M	$234.03M	$185.53M
Total Assets	$175.97M	$206.74M	$242.53M	$513.59M	$504.61M	$521.07M
Current Liabilities	$66.63M	$86.64M	$94.40M	$99.24M	$89.49M	$95.59M
Long-Term Debt	$44.93M	$37.45M	$29.97M	$22.48M	$14.99M	—
Total Debt	$61.07M	$61.04M	$60.88M	$53.30M	$45.72M	$39.95M
Total Liabilities	$157.41M	$124.80M	$124.92M	$122.11M	$104.71M	$95.64M
Retained Earnings	-$1.38B	-$1.32B	-$1.29B	-$1.02B	-$1.01B	-$997.10M
Shareholders' Equity	$18.57M	$81.93M	$117.61M	$391.48M	$399.90M	$425.42M
Working Capital	$79.93M	$88.76M	$120.53M	$140.93M	$144.53M	$89.94M
Net Debt	$14.02M	$6.41M	$11.20M	$11.71M	$20.45M	—

RIGL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$893.00K	$30.54M	$24.03M	$21.98M	$2.73M	$30.65M
Free Cash Flow	-$893.00K	$30.54M	$24.02M	$21.99M	$2.73M	-$39.69M
Depreciation & Amortisation	$604.00K	$607.00K	$603.00K	$601.00K	$597.00K	$848.00K
Stock-Based Compensation	$3.32M	$3.28M	$3.36M	$2.75M	$3.46M	$6.84M
Investing Cash Flow	-$10.55M	-$23.28M	-$33.17M	-$25.36M	-$7.97M	$17.45M
Financing Cash Flow	$484.00K	$418.00K	$4.27M	-$4.57M	-$10.92M	-$11.70M
Share Repurchases	$0.00	$0.00	—	—	-$3.74M	-$511.00K
Net Change in Cash	-$10.96M	$7.68M	-$4.87M	-$7.95M	-$16.17M	$36.41M

Market Snapshot

About

Rigel Pharmaceuticals is a biotechnology company focused on discovering and developing small molecule drugs for hematologic disorders, cancer, and rare immune diseases. The company has developed approved therapies and maintains a pipeline of clinical and preclinical candidates. Rigel uses its expertise in intracellular signaling pathways to identify novel therapeutic targets.